Spray Valves/Nozzles That Are Used in Prescription and OTC Drugs Have Been Using The Same Valve Technology For The Past 100 Years, Until Now!
6 Business Verticals Identified. Each Represent In Excess of $1 Billion in Revenue! (2 of the 6 Applications are described below)
Curing Capital is pleased to present a Company with the first device, which will replace spray valve technology as we know it today. Current technology hasn’t changed in over 100 years. A perfect example of the old technology and how it fails on a daily basis are nasal sprays. We have all used them at one time or another with very limited results. What is unique about this device is that medication reaches the entire nasal cavity as well as the paranasal sinuses and is delivered so gently that there is virtually no sensation of liquid entering the nasal cavity to the patient. It eliminates taste, discomfort and most side effects associated with current nasal delivery devices. To date, over $6 Million has been spent by the CEO alone on this technology. Look at the market verticals and just one application embraced makes the numbers staggering.
To request a full package on the featured company please fill out the form below
Life Saving Technology:
This company has already demonstrated efficacy in humans in clinical trials with patients who have Alzheimer’s. A Phase I 21 patient study funded by the NIH was completed in 2007 with results published in the peer-reviewed journal Neurology magazine. Following the success of that clinical study a 90 patient Phase II program was undertaken, also funded by the NIH, and was completed in early 2010. This technology appeared in The Alzheimer’s Project on HBO and on ABC World News Tonight with Diane Sawyer and Maria Shriver.
Alzheimer’s is just one segment that is in serious need of this technology. But other sectors also have urgent requirements. The Company has reached an agreement with a specialty pharmaceutical company that is working on a treatment for brain tumors in which the device we have been speaking of is currently the only solution to the delivery of the drug into the patient. This technology allows reaching deep into the nasal cavity, up into the olfactory region, beyond where any other device can reach.
The Next Generation Delivery Device
The patented valve technology is designed to assist both pharmaceutical and consumer products. Here is a small list of liquid drugs the technology addresses directly:
- Nasal
- Ocular
- CNS (nose-to-brain)
- Dermal/Transdermal
- Throat
- Lungs
- Mouth
Company is the Recipient of the Frost Sullivan Award for Technology Excellence
There are a myriad of different uses in other industries including the $10 billion a year cosmetics industry. The Company was approached by the world’s largest fragrance manufacturer inquiring as to whether or not the technology could do the same thing with their liquids as it could do for pharmaceuticals. The same 100 year old valve technology that was failing patients and pharmaceutical companies, was also failing to allow the cosmetics companies to launch formulations their R&D had developed. Both pharmaceutical and cosmetic industry face similar problems nowadays in that the current technology cannot deliver “thick liquids” of high viscosity without loss of integrity in droplet size or flow control. This technology can handle these requirements with ease and has multiple applications. Sizeable test were repeatedly tried by different cosmetics and pharmaceutics companies, with huge success so far to date.
The world’s largest consumer healthcare company recently signed an agreement with the company to develop the next generation eye care delivery device.
This is the only technology that has the ability to produce any droplet size, atomization rate and exit velocity. Over 100 drugs in nasal alone are in development, most of which cannot be delivered with current technology. In the next five years, $100 billion in name-brand drugs are expected to go off-patent and this technology offers significantly improved life-cycle management.
Management:
Management and the Board have vast experience in managing and leading early stage and high growth companies.
CEO – An experienced Inventor, this industry veteran spent 13 years in high-tech manufacturing and has to his credit many inventions and new products as well as re-designed efficiency equipment for production manufacturing. One of his inventions has resulted in a projected savings of $5 million in annual production costs for just one use.
Executive VP – 20+ years of Business and Corporate Development experience. Has extensive in and out-licensing experience in the high technology and petro-chemical industries.
COO – 35+ years of experience in the medical device and pharmaceutical industries. His prior management roles have included: President of Surgical Specialties Corporation in Reading, PA and Vice President-International for American Home Products in St. Louis, MO, where he formed the international sales group and grew it into a $100+ million division.
The Opportunity:
Company is looking to raise $11,000,000 and will consider both institutional and syndicated financings with a minimum of $100,000 investment. The funds being raised are for Sales & Marketing and the establishment of Manufacturing as they transition out of R&D and into commercialization, and NOT for development purposes. If you would like to receive additional information, please contact us at the number listed below or reply to this email with your questions or request, and we will respond promptly.
